References
- Kovacs G , Berghold A , Scheidl S , Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009 Oct; 34 4: 888– 94.
- Hoeper MM , Bogaard HJ , Condliffe R , Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24; 62 25 Suppl: D42– D50.
-
Hatano
S
Strasser
T.
Primary Pulmonary Hypertension. Report on a WHO meeting.
World Health Organization meeting;
1973 Oct 15–17 ; Geneva, Switzerland. - Simonneau G , Gatzoulis MA , Adatia I , Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24; 62 25 Suppl: D34– D41.
- Peacock AJ , Murphy NF , McMurray JJ , Caballero L , Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007 Jul; 30 1: 104– 9.
- Humbert M , Sitbon O , Chaouat A , Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006 May 1; 173 9: 1023– 30.
- Jansa P , Jarkovsky J , Al-Hiti H , Epidemiology and long term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulm Med. 2014 Mar 15; 14: 45.
- Rich S , Dantzker DR , Ayres SM , Primary pulmonary hypertension. A national prospective surgery. Ann Intern Med. 1987 Aug; 107 2: 216– 23.
- Badesch DB , Raskob GE , Elliot CG , Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137 2: 376– 87.
- Frost AE , Badesch DB , Barst RJ , The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest. 2011 Jan; 139 1: 128– 37.
- Hoeper MM , Huscher D , Ghofrani HA , Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013 Sep 30; 168 2: 871– 80.
- Chung L , Farber HW , Benza R , Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 2014 Dec; 146 6: 1494– 504.
- Farber HW , Miller DP , Poms AD , Five-year outcomes of patients enrolled in the REVEAL registry. Chest. 2015 Oct; 148 4: 1043– 54.
- Benza RL , Miller DP , Gomberg MM , Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010 Jul 13; 122 2: 164– 72.
- Humbert M , Sitbon O , Chaouat A , Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010 Jul 13; 122 2: 156– 63.
- Pletra GG , Capron F , Stewart S , Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16; 43 12 Suppl S: 25S– 32S.
- Voelkel NF , Tuder RM , Weir EK. Pathophysiology of primary pulmonary hypertension. In: Rubin L , Rich S , editors. Primary pulmonary hypertension. New York: Marcel Dekker; 1997. p. 83– 129.
- Farber HW Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004 Oct 14; 351 16: 1655– 65.
- Christman BW , McPherson CD , Newman JH , An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992 Jul 9; 327 2: 70– 5.
- Stewart DJ , Levy RD , Cernacek P , Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991 Mar; 114 6: 464– 9.
- Ghofrani HA , Pepke-Zaba J , Barbera JA , Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43 12 Suppl S: 68S– 72S.
- Glaid A , Yanagisawa M , Langleben D , Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993 Jun 17; 328 24: 1732– 9.
- Vincent JA , Ross RD , Kassab J , Hsu JM , Pinsky WW. Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow. Am J Cardiol. 1993 May 15; 71 13: 1204– 7.
- Steiner MK , Syrkina OL , Kolliputi N , Mark EJ , Hales CA , Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009 Jan 30; 104 2: 236– 44.
- Loyd JE , Primm RK , Newman JH. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis. 1984 Jan; 129 1: 194– 7.
- Fessel J , Loyd J , Austin E. The genetics of pulmonary arterial hypertension in the post-BMPR2 era. Pulm Circ. 2011 Jul–Sep; 1 3: 305– 19.
- Trembath R , Thomson J , Machado R , Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2001 Aug 2; 345 5: 325– 34.
- Umar S , Rabinovitch , Eghbali . Estrogen Paradox in Pulmonary Hypertension. Am J Resp Crit Care Med. 2012 Jul 15; 186 2: 125– 31.
- Austin ED , Hamid R , Hemnes AR , BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ. 2012 Feb 20; 3 1: 6.
- Atkinson C , Stewart S , Upton PD , Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002 Apr 9; 105 14: 1672– 8.
- Boggaard HJ , Abe K , Vonk Noordegraaf A , Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right heart failure in pulmonary circulation. Chest. 2009 Mar; 135 3: 794– 804.
- Aguero J , Ishikawa K , Hadri L , Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model. Am J Physiol Heart Circ Physiol. 2014 Oct 15; 307 8: H1204– 15.
- McLaughlin VV , Archer SL , Badesch DB , ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28; 53 17: 1573– 619.
- Sciomer S , Badagliacca R , Fedele F. Pulmonary hypertension: echocardiographic assessment. Ital Heart J. 2005; 6: 840– 5.
- Bossone E , Duong-Wagner TH , Paciocco G , Echocardiographic features of primary pulmonary hypertension. J Am Soc Echocardiogr. 1999 Aug; 12 8: 655– 62.
- Ling LF Marwick TH. Echocardiographic assessment of right ventricular function: How to account for tricuspid regurgitation and pulmonary hypertension. JACC Cardiovasc Imaging. 2012 Jul; 5 7: 747– 53.
- Galiè N , Humbert M , Vachiery JL , 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015 Oct; 46 4: 903– 75.
- Ryan JJ , Rich JD , Thiruvoipati T , Swamy R , Kim GH , Rich S. Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J. 2012 Apr; 163 4: 589– 94.
- Tonelli AR , Alnuaimat H , Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med. 2010 Apr; 104 4: 481– 96.
- Barnett CF , Alvarez P , Park MH. Pulmonary Arterial Hypertension: Diagnosis and Treatment. Cardiol Clin. 2016 Aug; 34 3: 375– 89.
- Boxt LM Katz J. Magnetic resonance imaging for quantitation of right ventricular volume in patients with pulmonary hypertension. J Thorac Imaging. 1993; 8: 92– 7.
- Swift AJ , Rajaram S , Condliffe R , Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension: results from the ASPIRE registry. J Cardiovasc Magn Reson. 2012 Jun 21; 14: 40.
- Peacock AJ , Crawley S , McLure L , Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. Circ Cardiovasc Imaging. 2014 Jan; 7 1: 107– 14.
- Trip P , Nossent EJ , de Man FS , Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur Respir J. 2013 Dec; 42 6: 1575– 85.
- Sun XG , Hansen JE , Oudiz RJ , Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol. 2003 Mar 19; 41 6: 1028– 35.
- Jilwan FN , Escourrou P , Garcia G , Jaïs X , Humbert M , Roisman G. High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest. 2013 Jan; 143 1: 47– 55.
- Rafanan AL , Golish JA , Dinner DS , Hague LK , Arroliga AC. Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest. 2001 Sep; 120 3: 894– 9.
- Barst R , Lewis R , Long W , A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1; 334 5: 296– 301.
- Galiè N , Corris PA , Frost A , Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 Dec 24; 62 25 Suppl: D60– 72.
- Simonneau G , Barst RJ , Galiè N , Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002; 165: 800– 4.
- Mather M , McDevitt S , Saggar R. Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations. J Heart Lung Transplant. 2010 Nov; 29 11: 1210– 7.
- Tapson VF , Gomberg-Maitland M , McLaughlin V , Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006 Mar; 129 3: 683– 8.
- McLaughlin VV , Benza RL , Rubin LJ , Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010 May 4; 55 18: 1915– 22.
- Jing ZC , Parikh K , Pulido T , Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013 Feb 5; 127 5: 624– 33.
- Tapson VF , Jing ZC , Xu KF , Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013 Sep; 144 3: 952– 8.
- Olschewski H , Simonneay G , Galiè N , Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug 1; 347 5: 322– 9.
- Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010 Jan; 104 1: 9– 21.
- Kuwano K , Hashino A , Asaki T , 2-[4-[(5,6-diphenylpyrazin-2-yl) (isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007 Sep; 322 3: 1181– 8.
- Simonneau G , Lang I , Torbicki A , Efficacy, safety, and tolerability of ACT-293987, a novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: results from a phase IIa study in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med. 2010; 181: A2515.
- Sitbon O , Channick R , Chin KM , Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24; 373 26: 2522– 33.
- Rubin LJ , Badesch DB , Barst RJ , Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21; 346 12: 896– 903.
- Galiè N , Olschewski H , Oudiz R , Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10; 117 23: 3010– 9.
- Pulido T , Adzerikho I , Channick RN , Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29; 369 9: 809– 18.
- Channick RN , Delcroix M , Ghofrani HA , Effect of macitentan on hospitalizations: results from SERAPHIN trial. JACC Heart Fail. 2015 Jan; 3 1: 1– 8.
- Galiè N , Ghofrani HA , Torbicki A , .; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17; 353 20: 2148– 57.
- Galiè N , Brundage BH , Ghofrani HA , Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009 Jun 9; 119 22: 2894– 903.
- Mathai SC , Hassoun PM , Puhan MA. Sex differences in response to tadalafil in pulmonary arterial hypertension. Chest. 2015 Jan; 147 1: 188– 97.
- Gabler NB , French B , Strom BL. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest. 2012 Jan; 141 1: 20– 6.
- Ghofrani HA , Galiè N , Grimminger F , Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25; 369 4: 330– 40.
- Ghofrani HA , Hoeper MM , Halank M , Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J. 2010 Oct; 36 4: 792– 9.
- Rich S , Kaufmann E , Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992 Jul 9; 327 2: 76– 81.
- Badesch DB , Abman SH , Ahearn GS , Medical therapy for pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul; 126 1 Suppl: 35S– 62S.
- Barst RJ , Gibbs SR , Hossein A , Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54 1 Suppl: S78– 84.
- Sitbon O , Humbert M , Jais X , Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005 Jun 14; 111 23: 3105– 11.
- Taichman DB , Ornelas J , Chung L , Pharmacologic therapy for pulmonary hypertension in adults: CHETS guideline and expert panel report. Chest. 2014 Aug; 146 2: 449– 75.
- Galiè N , Barbera J , Frost W , Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015 Aug 27; 373: 834– 44.
- Hemnes AR , Kiely DG , Cockrill BA , Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015 Sep; 5 3: 435– 65.
- Jaïs X , Olsson KM , Barberà JA , Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J. 2012 Oct; 40 4: 881– 5.
- Lund CJ Donovan JC. Blood volume during pregnancy: significance of plasma and red cell volumes. Am J Obstetr Gynecol. 1967 Jun 1; 98 3: 393– 403.
- Robson SC , Hunter S , Moore M , Dunlop W. Haemodynamic changes during the puerperium: a Doppler and M-mode echocardiographic study. Br J Obstetr Gynaecol. 1987 Nov; 94 11: 1028– 39.
- Lahm T , Patel KM , Crisostomo PR , Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Am J Physiol Endocrinol Metab. 2007 Jun 26; 293 3: E865– E871.
- Mantha S , Karp R , Raghavan V , Terrin N , Bauer KA , Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012 Aug 7; 345: e4944.
- Regitz-Zagrosek V , Lundqvist CB , Borghi C , ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011 Dec; 32 24: 3147– 97.
- Terek D , Kayikcioglu M , Kultursay H , Pulmonary arterial hypertension and pregnancy. J Res Med Sci. 2013 Jan; 18 1: 73– 6.
DOI: https://doi.org/10.14797/mdcj-13-4-224 | Journal eISSN: 1947-6108
Language: English
Page range: 224 - 237
Published on: Oct 1, 2017
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2017 Humna Abid Memon, Myung H. Park, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.